Neosynephrin-Pos (Phenylephrine Hydrochloride)

Phenylephrine is a selective alpha‑1 adrenergic receptor agonist. When applied to the eye, it contracts the radial iris muscle, causing pupil dilation, and narrows conjunctival vessels, which reduces redness. The effect is localized and rapid.

The specific dosing regimen for Neosynephrin-Pos is determined by the prescribing clinician based on the indication, patient age, and clinical response. The prescriber will set the number of drops and frequency appropriate for each case.

Safety data for phenylephrine ophthalmic use in pregnancy or lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing to pregnant or nursing individuals.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neosynephrin-Pos (phenylephrine) provides rapid pupil dilation primarily via alpha‑1 stimulation, whereas agents like tropicamide act on muscarinic receptors. Phenylephrine may cause less cycloplegia but can increase intra‑ocular pressure in susceptible patients, making choice dependent on clinical needs.

Neosynephrin-Pos should be stored at room temperature, below 25 °C, in its original container. Protect the solution from light and moisture, and keep the cap tightly closed to maintain sterility.

The solution is applied topically to the conjunctival sac. Typically, one or two drops are instilled in the affected eye(s) as directed by the prescriber, with care to avoid contamination of the dropper tip.

Serious risks include a sustained rise in intra‑ocular pressure, especially in patients with narrow‑angle glaucoma, and systemic hypertension or tachycardia if significant absorption occurs. Rarely, severe allergic reactions or retinal artery occlusion may occur.

Neosynephrin-Pos should be avoided in patients with known hypersensitivity to phenylephrine, uncontrolled hypertension, narrow‑angle or angle‑closure glaucoma, and in individuals taking MAO inhibitors. Contra‑indications are determined by the prescribing clinician.